Authors:
The use of spectral Flow Cytometry has the potential to significantly increase the data collected through clinical studies. Recent technology advancements and increased availability of fluorochromes have resulted in a dramatic rise in the complexity and dimensionality of flow cytometry panels. While increasing the panel size enables detection of a broader spectrum of markers and subpopulations, even in small biological samples, it also introduces several obstacles in panel design, optimization, and downstream data processing and interpretation.
In this collaborative special report in Bioanalysis, the authors share their experiences and methodologies for developing high-dimensional panels for the Aurora spectral flow cytometer to facilitate enhanced clinical sample analysis.
Q2 Solutions Innovation Laboratories is located in the heart of the dynamic Research Triangle Park and within our global headquarters in Durham, NC, USA. This facility creates an innovative...
In this episode, Megan McCausland, Scientific Advisor for Flow Cytometry at Q2 Solutions, and Scott Bornheimer, Associate Director of Medical and Scientific Affairs at BD Biosciences, discuss the...
In today's evolving, dynamic clinical development environment, central laboratories must adapt to meet the growing demand for early biomarker evaluation before advancement into clinical trials....